Anzeige
Mehr »
Dienstag, 19.08.2025 - Börsentäglich über 12.000 News
+62% Kurspotenzial: Jetzt handeln?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P208 | ISIN: US68622P1093 | Ticker-Symbol: 4TZ
Tradegate
19.08.25 | 09:07
8,600 Euro
+1,18 % +0,100
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
ORIC PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ORIC PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
8,3508,60013:40
8,3508,60012:20

Aktuelle News zur ORIC PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoORIC Pharmaceuticals: ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer51SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...
► Artikel lesen
MiOric lays off 20% of workforce to strengthen focus on clinical-stage cancer drugs1
ORIC PHARMACEUTICALS Aktie jetzt für 0€ handeln
12.08.ORIC Pharmaceuticals GAAP EPS of -$0.471
12.08.Oric Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
12.08.Oric Pharmaceuticals, Inc. - 8-K, Current Report1
01.08.ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)105SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...
► Artikel lesen
08.07.Ladenburg Thalmann initiates ORIC Pharmaceuticals stock with Buy rating2
03.07.ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)105SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...
► Artikel lesen
13.06.Oric Pharmaceuticals, Inc. - 8-K, Current Report1
11.06.Oric Pharmaceuticals files to sell 19.23M shares of common stock by selling shareholders1
06.06.ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)130SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...
► Artikel lesen
29.05.ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital1
29.05.ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study1
29.05.ORIC Pharmaceuticals shares surge on promising trial data1
29.05.Cantor Fitzgerald behält Overweight-Bewertung für ORIC Pharmaceuticals bei3
29.05.Cantor Fitzgerald maintains Overweight on ORIC Pharmaceuticals stock1
29.05.ORIC Reports Promising Efficacy & Safety Data From ORIC-944 Phase 1b Trial In MCRPC; Stock Up-
28.05.ORIC Pharmaceuticals announces $125M private placement to advance cancer pipeline1
28.05.Oric Pharmaceuticals, Inc. - 8-K, Current Report4
28.05.ORIC Pharmaceuticals sichert sich 125 Millionen US-Dollar durch Privatplatzierung1
Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1